<DOC>
	<DOC>NCT02452450</DOC>
	<brief_summary>The purpose of this study was to determine rates of absorption of Ibuprofen and Paracetamol formulations.</brief_summary>
	<brief_title>Ibuprofen and Paracetamol Pharmacokinetic Study</brief_title>
	<detailed_description />
	<mesh_term>Acetaminophen</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>1. Age: &gt; 18 to &lt; 50 years. 2. Sex: Male and female subjects are eligible for entry. 3. Female subject of child bearing potential with a negative pregnancy test at the screening visit and willing to use an effective method of contraception, if applicable 4. Female subject of nonchild bearing potential with negative pregnancy test at the screening visit. 5. Male subject willing to use an effective method of contraception. 6. Status: Healthy volunteers with a body mass index of &gt;18 and &lt;30 kg/m2. 7. Absence of relevant abnormalities in the clinical examination, ECG, drug and safety analysis. 8. Subjects who have given written informed consent 1. Pregnant or lactating female subjects. 2. A history of significant disease of any bodysystem. 3. Any condition that may currently interfere with the absorption, distribution, metabolism or excretion of drugs. 4. A history of allergy or intolerance (including angiooedema, urticaria, bronchospasm and rhinitis) related to treatment with ibuprofen, aspirin or other nonsteroidal antiinflammatory drugs (NSAIDs), paracetamol, or the excipients of the formulations. 5. A history of peptic or duodenal ulcers or gastrointestinal bleed or upper gastrointestinal bleed, or other significant gastrointestinal disorders. 6. A history of frequent dyspepsia, e.g., heartburn or indigestion. 7. A history of migraine. 8. A history of psychotic illness, attempted suicide or parasuicide. 9. Current smokers and exsmokers who have smoked within 6 months. 10. A history of drug abuse (including alcohol). 11. High consumption of stimulating drinks 12. Those with positive drugs of abuse screen including alcohol on any occasion throughout the study. 13. Ingestion of a prescribed drug at any time in the 14 days before dosing with study medication (excluding hormonal contraceptives and hormone replacement therapy), or consumption of enzyme inhibitors or inducers during the previous month (such as barbiturates, carbamazepine, erythromycin, phenytoin, etc). 14. Ingestion of an overthecounter preparation within 7 days before dosing with study medication, including herbal medications, vitamin/fish oil supplements, ibuprofen and other NSAIDs and paracetamol. 15. Donation of blood in quantity in the previous 12 weeks before enrolment into the study 16. Known human immune deficiency virus (HIV) positive status, or a positive viral serology screen. 17. Topical use of ibuprofen within 7 days before dosing with study medication 18. Those previously randomised into this study. 19. Employee at study site. 20. Partner or first degree relative of the investigator. 21. Those with an ibuprofen level &gt; 10 ng/ml as determined at prestudy screening visit 2 (Part 2 (Pivotal Phase) of the study only). 22. Those who are unwilling to consume gelatin of animal origin (Part 2 (Pivotal Phase) of the study only). 23. Those who have participated in a clinical trial in the previous 12 weeks 24. Those unable in the opinion of the Investigator to comply fully with the study requirements.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>